{"version":"1.0","provider_name":"Jordan News Gazette","provider_url":"https:\/\/jordannewsgazette.com","author_name":"jadmin","author_url":"https:\/\/jordannewsgazette.com\/author\/jadmin\/","title":"ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson\u2019s Disease - Jordan News Gazette","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"CBURrjZqhG\"><a href=\"https:\/\/jordannewsgazette.com\/abl-bio-enters-global-collaboration-and-license-agreement-with-sanofi-to-advance-abl301-for-the-treatment-of-parkinsons-disease\/\">ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson\u2019s Disease<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/jordannewsgazette.com\/abl-bio-enters-global-collaboration-and-license-agreement-with-sanofi-to-advance-abl301-for-the-treatment-of-parkinsons-disease\/embed\/#?secret=CBURrjZqhG\" width=\"600\" height=\"338\" title=\"&#8220;ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson\u2019s Disease&#8221; &#8212; Jordan News Gazette\" data-secret=\"CBURrjZqhG\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson\u2019s disease ABL301 uses ABL\u2019s Grabody-B platform technology to effectively cross the blood-brain barrier ABL to receive $75M upfront and up to $985M in potential milestone payments for exclusive [\u2026]","thumbnail_url":"https:\/\/ci5.googleusercontent.com\/proxy\/neCKdBnbgnxJUs_5Zotd8AIe0Pt8J9zkXgG-ricSxd4GXwUWDPZWA7xAUMpsK_v0ZqF_cjNNtb7gQpTEfaEw7KFW8TVmH_kChwQ3iEXhYt_Hysj_=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1724570\/Image_Sanofi_ABL_Bio.jpg"}